Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Veru’s obesity drug roughly as safe as Wegovy; Keros’ board fight
Last month
News Briefing
A new dawn for psychedelics? Compass could be the first to find out
Last month
Pharma
In Focus
Post-Hoc Live: Is biotech sentiment really as bad as it seems?
Last month
Financing
Deals
Strand Therapeutics reports promising start for mRNA cancer therapy
Last month
R&D
Updated: MD Anderson-allied investment firm targets $250M for second cancer biotech fund
Last month
Financing
Startups
InflaRx cans Gohibic development after skin disease trial stopped for futility
Last month
R&D
Axsome and Hetero settle patent fight over sleep disorder drug
Last month
Pharma
Law
Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined
Last month
Deals
FDA leadership preps for summer biopharma listening tour across six cities
Last month
FDA+
FDA rejects Savara’s rare lung disease drug over limited manufacturing data
Last month
Pharma
FDA+
Sernova chair resigns following insider trading indictment over Novartis-Chinook deal
Last month
People
Law
Boundless Bio changes plans for cancer drug after toxicity issues
Last month
People
R&D
RFK Jr. ends annual Covid vaccine recommendations for kids, pregnant women
Last month
FDA+
Lilly to buy non-opioid pain biotech SiteOne for up to $1B
Last month
Deals
Pharma
Liquidia wins approval for inhaled hypertension drug in two settings, furthering rivalry with United Therapeutics
Last month
Pharma
FDA+
ITM reveals up to $262M debt financing; Caris Life Sciences to go public
Last month
News Briefing
Gilgamesh’s short-acting psychedelic drug shows rapid effect in Phase 2 depression study
Last month
R&D
Biogen taps City Therapeutics in RNAi deal worth up to $1B
Last month
Startups
Deals
Brooklyn Health raises $6.5M to standardize mental health assessment
Last month
Financing
Health Tech
Blackstone's GRIN inks epilepsy licensing deal with Angelini, closes $140M Series D
Last month
Deals
Pharma
Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA
Last month
Cell/Gene Tx
FDA+
Prothena’s amyloidosis drug flops again, spending and staff cuts are on the way
Last month
People
R&D
Investors pump $130M into protein degrader startup GlycoEra
Last month
Financing
Startups
Syndeio debuts with $90M+ to bring together synapse repair drugs
Last month
Financing
First page
Previous page
14
15
16
17
18
19
20
Next page
Last page